Shelton Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$298K Sell
3,807
-151
-4% -$10.3K 0.01% 546
2026
Q1
$256K Hold
3,958
0.01% 572
2025
Q4
$266K Sell
3,958
-555
-12% -$37.3K 0.01% 538
2025
Q3
$331K Hold
4,513
0.01% 475
2025
Q2
$235K Sell
4,513
-116
-3% -$6.6K 0.01% 601
2025
Q1
$295K Sell
4,629
-152
-3% -$8.83K 0.01% 477
2024
Q4
$229K Sell
4,781
-340
-7% -$17.4K 0.01% 632
2024
Q3
$293K Hold
5,121
0.01% 513
2024
Q2
$268K Sell
5,121
-614
-11% -$26.9K 0.01% 536
2024
Q1
$233K Hold
5,735
0.01% 647
2023
Q4
$212K Sell
5,735
-568
-9% -$21.4K 0.01% 671
2023
Q3
$241K Hold
6,303
0.01% 565
2023
Q2
$227K Sell
6,303
-559
-8% -$19.1K 0.01% 639
2023
Q1
$262K Hold
6,862
0.01% 542
2022
Q4
$390K Sell
6,862
-412
-6% -$21.1K 0.04% 338
2022
Q3
$288K Hold
7,274
0.01% 465
2022
Q2
$320K Hold
7,274
0.01% 448
2022
Q1
$290K Hold
7,274
0.01% 573
2021
Q4
$292K Hold
7,274
0.01% 574
2021
Q3
$296K Hold
7,274
0.01% 558
2021
Q2
$330K Hold
7,274
0.01% 529
2021
Q1
$303K Hold
7,274
0.01% 553
2020
Q4
$311K Buy
+7,274
New +$261K 0.01% 481

Other funds holding HALO

Shelton Capital Management's HALO Position: Q2 2026 in Review

Shelton Capital Management reduced its Halozyme (HALO) stake by 3.8% in Q2 2026, selling an estimated $10.3K and leaving 3,807 shares worth $298K. The position accounts for 0.01% of the portfolio, ranked #546.

Shelton Capital Management first reported a position in HALO in Q4 2020 and has held it in 23 quarters since. The position peaked at $390K in Q4 2022. 671 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Shelton Capital Management held 3,807 shares of Halozyme worth $298K as of Q2 2026.
  • Shelton Capital Management sold 151 Halozyme shares in Q2 2026, an estimated $10.3K.
  • Halozyme made up 0.01% of Shelton Capital Management's portfolio in Q2 2026, its #546 holding.
  • Shelton Capital Management first reported a position in Halozyme in Q4 2020 and has held it in 23 quarters since.
  • Shelton Capital Management's Halozyme position peaked at $390K in Q4 2022.
  • 671 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Shelton Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.